- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
On Tuesday, Summit Therapeutics Inc (SMMT:NMQ) closed at 4.39, -18.55% below its 52-week high of 5.39, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.52 |
---|---|
High | 4.61 |
Low | 4.35 |
Bid | 4.36 |
Offer | 4.49 |
Previous close | 4.54 |
Average volume | 1.74m |
---|---|
Shares outstanding | 701.98m |
Free float | 83.23m |
P/E (TTM) | -- |
Market cap | 3.19bn USD |
EPS (TTM) | -0.1657 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼